You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 62 No. 2, February 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  This Month in Archives of Neurology
 This Article
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

This Month in Archives of Neurology

Arch Neurol. 2005;62:181-182.

NEUROBIOTECHNOLOGY 2005

This theme issue explores new and emerging biotechnologies that will enhance our knowledge of neurological disease. The first 7 article titles noted below relate to this theme.


Mouse Models of Human Neurodegenerative Disorders

Bloom and colleagues (SEE ARTICLE) emphasize that transgenic mouse models offer opportunities to detect and follow pathologic progression and provide potential biomarkers by which to assess therapeutic interventions for human neurodegenerative disease. Evidence for Alzheimer disease suggests some starting requirements for the experimental data that could enhance the likelihood of developing medications in these mouse models that would be effective in humans.


Defining Molecular Targets to Prevent Alzheimer Disease

Selkoe (SEE ARTICLE) predicts that middle-aged adults will commonly undergo a formal risk assessment for Alzheimer disease that will include measurements of plasma {beta}-amyloid and perhaps cerebrospinal fluid {beta}-amyloid and tau levels, and quantitative assessment of brain {beta}-amyloid burden by imaging procedures. Based on the results, patients would be offered 1 of several potentially disease-slowing therapies. The future approach to Alzheimer disease is identification of disease in its earliest state and initiation of specific therapy to prevent progression of its clinical expression.


Figure. The proteolytic processing of {beta}-amyloid precursor protein and the fate of amyloid {beta}-protein.



Imaging Technology for Neurodegenerative Diseases

Mathis and colleagues (SEE ARTICLE) describe advances in neuroimaging over the past 2 decades. Recent advances in imaging {beta}-amyloid plaques offer a great technological breakthrough and present the possibility for more efficient assessment of anti-amyloid interventions as well as specific noninvasive diagnostic capabilities.


Laser Capture Microdissection in the Study of Neurodegenerative Disease

Standaert (SEE ARTICLE) points out that laser capture microdissection is a new technology that is becoming increasingly important for studies of neurodegenerative disease. In the near future, this powerful new tool will provide important insights into the etiology of neurodegenerative diseases and the basis of selective vulnerability.


Blood Gene Expression Profiling of Neurologic Diseases

Tang and colleagues (SEE ARTICLE) present data concerning the association of neurological diseases with unique patterns of up- and down-regulated genes in whole blood. Patients with neurofibromatosis, epilepsy, and Tourette syndrome were studied for their blood gene expression levels of greater than 12 000 genes measured with Affymetrix U95A arrays. They find that in general blood gene expression profiling can provide surrogate markers for neurological diseases.


Fate of Human Neuronal Progenitor Cells Transplanted in Rat Spinal Cord

Li and colleagues (SEE ARTICLE) have transplanted immortalized human neuronal progenitor cells into the rat spinal cord. They were rejected after 4 weeks, despite cyclosporine immunosuppression. Their results suggest that the xenotransplantation failed because of apoptotic cell death, possibly involving natural killer cells. The techniques and methods developed in this research program will be vital to subsequent work on attempts to transplant cells into injured human spinal cord.


Genomics of Oxidative Stress in Glioma

Fathallah-Shaykh (SEE ARTICLE) utilizes specific genome-scale expression discovery to identify genes differentially expressed in cultured glioma cells vs normal brain tissue. The discovered states of expression show a cohesive molecular system that protects rapidly growing glioma cells from endoplasmic reticulum and oxidative stress–induced apoptosis.


Rasagiline in Levodopa-Treated Parkinson Disease: The PRESTO Study

The Parkinson Study Group (SEE ARTICLE) has studied the safety, tolerability, and efficacy of rasagiline, a selective monoamine oxidase type B inhibitor, in levodopa-treated patients with Parkinson disease (PD) with motor fluctuations. Rasagiline improves motor fluctuations and PD symptoms in levodopa-treated patients with PD. It is a promising new treatment for PD.


Intravenous Methylprednisolone in Treating Polyneuropathy

Lopate and colleagues (SEE ARTICLE) have studied the efficacy and safety of high-dose, intermittent intravenous methylprednisolone as initial and chronic maintenance therapy for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). They report that treatment of patients with CIDP using intermittent intravenous methylprednisolone results in improved strength equal to that found with the use of intravenous immunoglobulin and oral prednisone.


Rituximab on B Cells in Patients With Primary Progressive Multiple Sclerosis

Monson and colleagues (SEE ARTICLE) show that rituximab, an anti-CD20 monoclonal antibody that depletes CD20+ B cells, in patients with primary progressive multiple sclerosis temporarily suppressed the activation state of B cells in cerebrospinal fluid. The effects are limited in comparison with the effects in the periphery and will need to be confirmed in a larger group of patients.


High Prevalence of Ulnar Neuropathy in Patients Receiving Hemodialysis

Nardin and colleagues (SEE ARTICLE) show there is a high prevalence of ulnar neuropathy in patients with end-stage renal disease receiving hemodialysis. Ulnar neuropathy was documented in 51% of 73 patients, and preventive measures are indicated.


Fatigue and the Hypothalamo-Pituitary-Adrenal Axis in Multiple Sclerosis

Gottschalk and colleagues (SEE ARTICLE) describe a high level of activity of the hypothalamo-pituitary-adrenal axis in patients with multiple sclerosis with fatigue compared with those without fatigue.


Structural Changes in Parkinson Disease With Dementia

Summerfield and colleagues (SEE ARTICLE) studied magnetic resonance images in patients with Parkinson disease with and without dementia and also in healthy age-matched controls using voxel-based morphometry analyses of gray matter. The hippocampus, thalamus, and anterior cingulate were the regions most affected in dementia in Parkinson disease.


Active Head-Impulse Test in Vestibulopathy

Black and colleagues (SEE ARTICLE) show that passive head-impulses are necessary to detect a severe unilateral peripheral vestibulopathy and that active head-impulses will produce a false-negative result.


Functional Correlates and Prevalence of Mild Parkinsonian Signs in a Community Population of Older People

Louis and colleagues (SEE ARTICLE) show that mild parkinsonian signs, and particularly axial dysfunction, were associated with functional disability in a community population.







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.